FCM
FATE icon

Farallon Capital Management’s Fate Therapeutics FATE Stock Holding History

Farallon Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,900
Closed -$1.24M – 320
2022
Q1 		$1.24M Sell
31,900
-725,525
-96% -$28.1M 0.01% 216
2021
Q4 		$44.3M Sell
757,425
-1,553,973
-67% -$88.1M 0.22% 71
2021
Q3 		$137M Buy
2,311,398
+406,398
+21% +$31.9M 0.64% 44
2021
Q2 		$165M Buy
1,905,000
+5,000
+0.3% +$403K 0.68% 39
2021
Q1 		$157M Sell
1,900,000
-1,100,000
-37% -$105M 0.78% 37
2020
Q4 		$273M Sell
3,000,000
-125,000
-4% -$7.76M 1.64% 26
2020
Q3 		$125M Sell
3,125,000
-375,000
-11% -$13.1M 0.86% 41
2020
Q2 		$120M Buy
3,500,000
+500,000
+17% +$14.9M 0.96% 36
2020
Q1 		$66.6M Buy
3,000,000
+750,000
+33% +$19M 0.57% 35
2019
Q4 		$44M Hold
2,250,000
– – 0.3% 60
2019
Q3 		$34.9M Sell
2,250,000
-250,000
-10% -$4.79M 0.26% 57
2019
Q2 		$50.8M Hold
2,500,000
– – 0.33% 56
2019
Q1 		$43.9M Buy
2,500,000
+300,000
+14% +$4.74M 0.33% 56
2018
Q4 		$28.2M Buy
2,200,000
+1,670,000
+315% +$23.3M 0.21% 61
2018
Q3 		$8.63M Buy
+530,000
New +$6.27M 0.05% 86
2014
Q4 		– Sell
-171,196
Closed -$880K – 92
2014
Q3 		$880K Sell
171,196
-76,906
-31% -$445K 0.01% 82
2014
Q2 		$1.57M Sell
248,102
-26,898
-10% -$189K 0.02% 90
2014
Q1 		$2.68M Sell
275,000
-269,243
-49% -$2.08M 0.05% 70
2013
Q4 		$3.42M Buy
+544,243
New +$3.43M 0.07% 70

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Farallon Capital Management's FATE Position: Q2 2022 in Review

Farallon Capital Management sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 31,900 shares — an estimated $1.24M sold.

Farallon Capital Management first reported a position in FATE in Q4 2013 and held it in 19 quarters. The position peaked at $273M in Q4 2020. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Farallon Capital Management reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Farallon Capital Management sold 31,900 Fate Therapeutics shares in Q2 2022, an estimated $1.24M.
  • Farallon Capital Management first reported a position in Fate Therapeutics in Q4 2013 and held it in 19 quarters.
  • Farallon Capital Management's Fate Therapeutics position peaked at $273M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Farallon Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.